Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients

Cancer Biology and Therapy

Volumn 13, Issue 5, 2012, Pages 264-271

  Ji, Minghua ^a   Tang, Jinhai ^a   Zhao, Jianhua ^a   Xu, Bin ^a   Qin, Jianwei ^a   Lu, Jianwei ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Anthracycline; Breast cancer; Chemotherapy; Clinical response; Disease free survival (DFS); Individualizing treatment; Polymorphism

Indexed keywords

ANTHRACYCLINE; CATALASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MANGANESE SUPEROXIDE DISMUTASE; MULTIDRUG RESISTANCE PROTEIN 1;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER STAGING; CHINESE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DRUG DETOXIFICATION; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84863251781     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.18920     Document Type: Article

References (29)

1. Davidson A, Gelmon K. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer? Future Oncol 2011; 7:37-55; PMID:21174537; http://dx.doi. org/10.2217/fon.10.163.
2. Blakey JD, Hall IP. Current progress in pharmacogenetics. Br J Clin Pharmacol 2011; 71:824-31; PMID:21235621; http://dx.doi.org/10.1111/j.1365- 2125.2011.03912.x.
3. Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005; 10:104-11; PMID:15709212; http://dx.doi. org/10.1634/theoncologist.10-2-104.
4. Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005; 65:1105-11; PMID:15705913.
5. Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 2008; 111:93-101; PMID:17922231; http://dx.doi.org/10.1007/s10549-007-9764-8.
6. Suresh A, Guedez L, Moreb J, Zucali J. Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br J Haematol 2003; 120:457-63; PMID:12580960; http://dx.doi. org/10.1046/j.1365-2141.2003.04074.x.
7. Sau A, Tregno FP, Valentino F, Federici G, Caccuri AM. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 2010; 500:116-22; PMID:20494652; http:// dx.doi.org/10.1016/j. abb.2010.05.012.
8. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, et al. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest 2010; 28:554-9; PMID:20210524; http://dx.doi. org/10.3109/07357900903286925.
9. Hamidovic A, Hahn K, Kolesar J. Clinical Significance of ABCB1 Genotyping in Oncology. J Oncol Pharm Pract 2010; 16:39-44; PMID:19401306; http://dx.doi. org/10.1177/1078155209104380.
10. Hoffimeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-8; PMID:10716719; http://dx.doi.org/10.1073/ pnas.050585397.
11. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2009; 78:49-55; PMID:18812689; http://dx.doi. org/10.1159/000158454.
12. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011; 28:265-9; PMID:20204543; http://dx.doi.org/ 10.1007/s12032-010-9456-9.
13. Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 2001; 22:827-9; PMID:11323405; http://dx.doi. org/10.1093/carcin/22.5.827.
14. Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, et al. A mitochondrial target sequence polymorphism in MnSOD predicts inferior survival in breast cancer patients treated with Cyclophosphamide. Clin Cancer Res 2009; 15:4165-73; PMID:19509150; http://dx.doi. org/10.1158/1078-0432.CCR- 09-0119.
15. Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005; 103:52-8; PMID:15565566; http://dx.doi. org/10.1002/cncr.20729.
16. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 65:437-46; PMID:19568750; http://dx.doi.org/10. 1007/s00280- 009-1046-1.
17. Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, et al. Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer 2008; 98:2006-10; PMID:18542066; http://dx.doi. org/10.1038/sj.bjc.6604394.
18. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao WD, Yu M, et al. Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936-42; PMID:12072547.
19. Oliveira AL, Rodrigues FFO, Santos RE, Aoki T, Rocha MN, Longui CA, et al. GSTT1, GSTM1 and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res 2010; 9:1045- 53; PMID:20568049; http://dx.doi.org/10.4238/vol9- 2gmr726.
20. Alpert LC, Schecter RL, Berry DA, Melnychuk D, Peters WP, Caruso JA, et al. Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res 1997; 3:661-7; PMID:9815734.
21. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25:1-6; PMID:10637601; http://dx.doi.org/10.1016/S0968- 0004(99)01493-0.
22. Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010; 10:62-9; PMID:19752884; http://dx.doi.org/10.1038/ tpj.2009.41.
23. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillnger R, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22:1117-21; PMID:12684679.
24. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71:297-303; PMID:11956513; http://dx.doi.org/10.1067/mcp.2002.122055.
25. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, et al. MDR1 polymorphisms predict the response to Etoposide-Cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006; 36:137- 41; PMID:16478794; http://dx.doi.org/10.1093/jjco/hyi231.
26. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16:56-63; PMID:15598939; http:// dx.doi.org/10.1093/annonc/mdi001.
27. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine- capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100:542-51; PMID:18398097; http:// dx.doi.org/10.1093/jnci/djn085.
28. Tang JH, Zhao JH, Wu JZ, Lu JW, Pan LQ, Xu ZY. Multiplex ligation-dependent SNPs genotyping method and its application in the detection of genes related to chemotherapy drugs in breast cancer. Chin J Oncol 2009; 31:108-13.
29. Eggerding FA. Fluorescent oligonucleotide ligation technology for identification of ras oncogene mutations. Mol Biotechnol 2000; 14:223-33; PMID:10890013; http://dx.doi.org/10.1385/MB:14:3:223.